Lakefront Biotherapeutics (LKFT) Current Leases (2017 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Current Leases for 11 consecutive years, with $1.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Leases fell 42.59% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (down 42.59% YoY), while the FY2025 annual figure was $2.0 million, down 45.86% from the prior year.
• Current Leases declined to $1.9 million in Q1 2026 per LKFT's latest filing, from $2.0 million in the prior quarter.
• Across five years, Current Leases topped out at $7.9 million in Q1 2022 and bottomed at $1.9 million in Q1 2026.
• Historically, Current Leases has averaged $4.4 million across 5 years, with a median of $4.5 million in 2024.
• Annual changes were most pronounced in 2022 — Current Leases fell 10.75% — and 2025, when it tumbled 56.21%.
• Lakefront Biotherapeutics' Current Leases stood at $7.4 million in 2022, then plunged by 31.95% to $5.0 million in 2023, then dropped by 25.73% to $3.7 million in 2024, then tumbled by 45.86% to $2.0 million in 2025, then decreased by 7.86% to $1.9 million in 2026.
• Business Quant data shows LKFT's Current Leases at $1.9 million in Q1 2026, $2.0 million in Q4 2025, and $2.0 million in Q3 2025.